Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 08, 2014; 82 (10 Supplement) April 29, 2014

Clinical Trial of Helminth-induced Immunomodulatory Therapy (HINT 2) in Relapsing-Remitting Multiple Sclerosis (P3.149)

John Fleming, Leslie Hartman, Jane Maksimovic, Sara Nace, Christopher Luzzio, Monica Koehn, Anna Ritter, Todd Risa, Benjamin Lawler, Andrea Maser, Pamela Mundt, Loren Rolak, Thomas Cook, Aaron Field, Zsuzsanna Fabry
First published April 9, 2014,
John Fleming
9University of Wisconsin, Madison Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leslie Hartman
8Radiology University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Maksimovic
8Radiology University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Nace
8Radiology University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Luzzio
10UW Health Department of Neurology Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Koehn
1Marshfield Clinic Marshfield WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Ritter
7Pathology and Laboratory Medicine University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Risa
3Radiology Marshfield Clinic Marshfield WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Lawler
2Neurology Marshfield Clinic Marshfield WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Maser
6Office of Clinical Trials University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela Mundt
4Clinical Research Center Marshfield Clinic Research Foundation Marshfield WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren Rolak
2Neurology Marshfield Clinic Marshfield WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Cook
5Biostatistics and Medical Informatics University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron Field
8Radiology University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zsuzsanna Fabry
7Pathology and Laboratory Medicine University of Wisconsin Madison WI United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Clinical Trial of Helminth-induced Immunomodulatory Therapy (HINT 2) in Relapsing-Remitting Multiple Sclerosis (P3.149)
John Fleming, Leslie Hartman, Jane Maksimovic, Sara Nace, Christopher Luzzio, Monica Koehn, Anna Ritter, Todd Risa, Benjamin Lawler, Andrea Maser, Pamela Mundt, Loren Rolak, Thomas Cook, Aaron Field, Zsuzsanna Fabry
Neurology Apr 2014, 82 (10 Supplement) P3.149;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To explore the safety and preliminary effectiveness of the helminth Trichuris suis ova (TSO) (porcine whipworm) in subjects with early relapsing-remitting multiple sclerosis (RRMS). BACKGROUND: The hygiene hypothesis suggests that the high level of sanitation in the modern environment (i.e., relative microbial deprivation) is one factor which may contribute to disordered immune regulation in putative autoimmune disorders, such as MS. DESIGN/METHODS: A baseline versus treatment design was employed in an exploratory clinical trial of 15 treatment naive, recently diagnosed RRMS subjects, each of whom underwent 5 months of pre-treatment observation and 10 months of treatment with TSO (2,500 live ova orally every two weeks). The primary outcome measures were 1) safety and tolerability of TSO and 2) changes in the number of gadolinium enhancing lesions (Gd+) during monthly brain MRI scans with double-dose gadolinium contrast which were read in random order by three masked radiologists. RESULTS: No significant safety or tolerability issues were observed. With 90% of timepoints analyzed to date, the mean number of Gd+ lesions per month was 3.2 during 5 months of observation and 2.1 during the last 5 months of treatment, a 34% relative reduction. Immunological assessments indicated that TSO was associated with increases in T regulatory cells and a modified Th2 immune response. Transcriptional analyses of peripheral blood mononuclear cells suggested that treatment led to diminished expression of the pellino E3 ubiquitin protein ligase 1 (pelli 1) gene, recently demonstrated to be a central activator of microglia in experimental autoimmune encephalomyelitis and possibly in MS itself. CONCLUSIONS: TSO appears safe and well-tolerated in RRMS subjects. The modest decrease observed in numbers of Gd+ lesions during treatment indicates that further studies if TSO will be required to assess its effectiveness in RRMS. Study Supported by: National Multiple Sclerosis Society Research Grant 3613A4/1

Disclosure: Dr. Fleming has nothing to disclose. Dr. Hartman has nothing to disclose. Dr. Maksimovic has nothing to disclose. Dr. Nace has nothing to disclose. Dr. Luzzio has nothing to disclose. Dr. Koehn has nothing to disclose. Dr. Ritter has nothing to disclose. Dr. Risa has nothing to disclose. Dr. Lawler has nothing to disclose. Dr. Maser has nothing to disclose. Dr. Mundt has nothing to disclose. Dr. Rolak has nothing to disclose. Dr. Cook has received personal compensation for activities with Biomarin, GlaxoSmithKline Inc., Zensun, Neuraltus, Merck & Co. Inc., and Advntrx. Dr. Field has nothing to disclose. Dr. Fabry has nothing to disclose.

Tuesday, April 29 2014, 3:00 pm-6:30 pm

  • Copyright © 2014 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise